LOS ANGELES--(BUSINESS WIRE)--
ImmunoCellular Therapeutics, Ltd. ("ImmunoCellular") (NYSE MKT: IMUC)
today announced initiation of a phase I clinical trial of cancer vaccine
ICT-121 as a potential treatment for patients with recurrent
glioblastoma multiforme (GBM). The investigator-sponsored phase I trial
is being conducted at Cedars-Sinai Medical Center in Los Angeles, CA, by
Jeremy Rudnick, MD, and ImmunoCellular is supporting the trial by
providing the ICT-121 vaccine. ICT-121 is a dendritic cell vaccine
targeting CD133, an important cancer stem cell marker that is commonly
overexpressed on a broad range of solid tumors.
The primary objective of the open label phase I trial is to assess the
safety and tolerability of ICT-121. Secondary objectives include overall
survival (OS) and progression-free survival (PFS) at six months after
surgery as well as other response parameters. Approximately 20 patients
who have had gross tumor resection and experience a first recurrence of
GBM, and who are HLA-A2 positive, will be treated in the trial. Patients
will be administered the vaccine once per week for four weeks during the
induction phase, followed by a maintenance phase consisting of one
treatment every two months until their supply of vaccine is depleted or
they experience progressive disease.
"The initiation of the ICT-121 trial completes another important
clinical milestone for ImmunoCellular and adds to the substantial
pipeline progress we have made this year in advancing our ICT-107 phase
II program in patients with newly diagnosed brain cancer," said Andrew
Gengos, ImmunoCellular Chief Executive Officer. "We are positioning our
company as an emerging leader in cancer immunotherapy by building our
dendritic cell-based vaccine pipeline, maintaining a strong financial
underpinning, and planning for the future should we achieve success in
our ongoing ICT-107 phase II trial. The second half of 2013 will be an
exciting time as we expect to reach the prescribed event level in the
ICT-107 trial that triggers analysis of the final results."
Earlier this year, ImmunoCellular announced that the US Patent and
Trademark Office (USPTO) issued a key patent application covering
ICT-121. The patent includes claims covering composition of matter as
well as methods of use. Specifically, the claims encompass immunogens
comprising a CD133 epitope and variants thereof as well as methods of
using such immunogens in immunization and to elicit cytotoxic T
lymphocyte responses that are specific for tumor cells expressing the
About ImmunoCellular Therapeutics, Ltd.
ImmunoCellular Therapeutics, Ltd. is a Los Angeles-based clinical-stage
company that is developing immune-based therapies for the treatment of
brain and other cancers. ImmunoCellular is conducting a phase II trial
of its lead product candidate, ICT-107, a dendritic cell-based vaccine
targeting multiple tumor-associated antigens for glioblastoma.
ImmunoCellular's pipeline also includes ICT-121, a dendritic cell
vaccine targeting CD133, and ICT-140, a dendritic cell vaccine targeting
ovarian cancer antigens and cancer stem cells. To learn more about
ImmunoCellular, please visit www.imuc.com.
Forward-Looking Statements for ImmunoCellular
This press release contains certain forward-looking statements that are
subject to a number of risks and uncertainties, including the risk that
ICT-107, ICT-121 and ICT-140 can be further successfully developed or
commercialized. Additional risks and uncertainties are described in
IMUC's most recently filed quarterly report on Form 10-Q and annual
report on Form 10-K. Except as permitted by law, IMUC undertakes no
obligation to update or revise any forward-looking statements, whether
as a result of new information, future events or otherwise.
ImmunoCellular Therapeutics, Ltd.
Green, 415-348-0010 (Direct) or 415-652-4819 (Mobile)
Source: ImmunoCellular Therapeutics, Ltd.
News Provided by Acquire Media